Deal Watch: Early 2020 Deal-Making Boom Starts With Third Bayer/Evotec R&D Alliance
The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.
You may also be interested in...
Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.
MYR’s Hepcludex obtained EU accelerated approval in July, making it the first approved therapy for hepatitis D. One analyst sees the drug as a blockbuster revenue opportunity for Gilead.
Small activating RNA research being pioneered by London, UK-based MiNA Therapeutics has attracted $30m in a series A funding, led by a tech billionaire-backed life sciences VC fund.